Upgrade to SI Premium - Free Trial

Biogen (BIIB), Eisai Expand Pact to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 Aducanumab

October 23, 2017 7:16 AM
Eisai Co., Ltd. and Biogen Inc. (NASDAQ: BIIB) announced today that the companies have expanded their existing agreement to jointly ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles